WESTLAKE, Texas--(BUSINESS WIRE)--Heart Test Laboratories, Inc. announces today the recent additions of Mr. John Q. Adams, Sr. and Mr. John D. Owen to further strengthen its Board of Directors.
“We are delighted to welcome two highly successful and experienced executives as Independent Members of Heart Test Labs’ Board of Directors. Their appointments come as product launch is imminent, and we position for an IPO or institutional capital in the coming months,” said Mr. Andrew Simpson, Chairman. “Their experience and track records of success in healthcare and strategic business management will help guide HTL in scaling around the world and to maximize the opportunity for the MyoVista®, a breakthrough in the early detection of heart disease.”
John Quincy Adams Sr.
Mr. Adams is a serial entrepreneur and has enjoyed a long career in the healthcare industry. In 1969, he founded Baylor Laboratories, Inc. which he sold to the Norwich Eaton Pharmaceutical division of Morton Norwich, Inc. in 1980. He then founded Allerderm, Inc. which was purchased by Vibrac, Inc. in 1985. In 1985, Mr. Adams founded Adams Laboratories, Inc. and sold it in 1992 to Medeva PLC, a listed company in the United Kingdom following which he served on Medeva’s Board of Directors until 1997 and as an Executive Director, holding various offices, until 1995. He later repurchased certain assets from Medeva to reform Adams Laboratories, Inc. in 1999 where he served as CEO until 2003. Adams Laboratories changed its name to Adams Respiratory Therapeutics, Inc. where Mr. Adams served as Chairman until October 2005 having led it through a highly successful IPO. Adams Respiratory developed prescription and non-prescription pharmaceuticals for the treatment of respiratory disorders and diseases, including Mucinex™, and was subsequently acquired by Reckitt Benckiser Group in late 2007.
Mr. Adams continues to be an active investor in healthcare companies and retains memberships and board positions in several professional and philanthropic organizations, including the American College of Allergy and the Vanderbilt University Voice Center. In July 2007, he was elected to the Board of Trustees for Heidelberg College in Tiffin, Ohio, and in April 2009 he was inducted into the Hall of Excellence of the Ohio Foundation of Independent Colleges. He is also an Honorary Fellow of the American Academy of Otolaryngology-Head and Neck Surgery. Mr. Adams holds a degree in Biology from Heidelberg College.
Mr. Owen was a co-founder of Jet Blue Airways and was its CFO for many years. During his tenure Jet Blue went from a start-up to a successful NASDAQ listed company with over $2 billion in revenue. John managed multiple public and private funding rounds as well as its IPO. Prior to JetBlue, Mr. Owen served as Treasurer for Southwest Airlines from 1984 to 1998. Subsequently, he served as CFO for Volotea Airlines during its start-up which included raising €65 million in equity financing before its commencement of flight operations in 2012. He holds a BA in Economics from SMU, summa cum laude and Phi Beta Kappa, and an MBA in Finance from the Wharton School where he was a Mayer Fellow. Mr. Owen is currently a full time private investor with a particular interest in the medical sector. Mr. Owen also chairs the Audit Committee of HTL.
About Heart Test Laboratories, Inc. (“HTL”)
HTL uses patented proprietary technology to develop medical devices that focus on the early detection of heart disease. Its first product, MyoVista®, represents a major clinical breakthrough in diagnostic electrocardiography. It significantly improves clinical efficacy, compared to conventional ECGs, in the early identification of ischemic and other cardiac dysfunctions.
MyoVista® applies advanced digital signal processing to create a high-sensitivity ECG with new proprietary informatics. It is ideally suited to both primary care and clinical environments in hospitals and outpatient care centers. MyoVista® uses standard 12-lead resting ECG protocols to characterize cardiac dysfunction with high accuracy, including for asymptomatic patients. It also displays standard 12-lead ECG information, including traditional interpretive analysis. MyoVista® promises to bridge the “diagnostic gap” found in heart disease today, namely the identification of “at risk” patients before suffering an adverse cardiac event, such as myocardial infarction.
The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training as well as easy and intuitive use.
Heart Disease results in 7 million deaths per year worldwide, more than all cancers combined; it represents the largest healthcare expenditure of any disease. Heart Test Laboratories is a privately held U.S. corporation. For more information, please visit www.hearttestlabs.com